|
A list of metabolites included in the metabolic profiling of the present study |
||||||||
| Compounds |
M/H/0 |
D/H/0 |
M/H/3 |
D/H/3 |
kw (P) |
corr coeffs |
M/H/10 |
D/H/10 |
|
|
||||||||
| Tyramine |
1.1 |
1.1 |
2.8 |
2.8 |
0.0074 |
0.66 |
2.1 |
1.2 |
| Dopamine |
-1.5 |
1.0 |
3.0 |
2.8 |
0.0045 |
0.88 |
1.7 |
1.4 |
| Tetradecanoic acid |
1.2 |
1.2 |
3.0 |
3.0 |
0.0045 |
0.65 |
3.0 |
1.0 |
| Glycine |
1.4 |
-1.3 |
2.8 |
2.1 |
0.0074 |
0.77 |
1.6 |
1.3 |
| Galacturonic acid |
1.4 |
1.3 |
3.0 |
3.0 |
0.0045 |
0.88 |
1.8 |
1.5 |
| Hexadecanoic acid |
-1.0 |
1.2 |
2.2 |
2.5 |
0.0118 |
0.58 |
2.1 |
1.0 |
| Acetate |
-1.4 |
-1.3 |
-3.0 |
-3.0 |
0.0045 |
-0.71 |
-2.6 |
-1.1 |
| Uridine |
1.4 |
1.4 |
2.5 |
1.3 |
0.0045 |
0.67 |
1.8 |
1.1 |
| Oleic acid |
-1.1 |
-1.1 |
2.2 |
-1.1 |
0.0118 |
0.67 |
1.2 |
1.8 |
| 3-Hydroxyproline |
-1.1 |
1.0 |
2.0 |
1.6 |
0.0284 |
0.64 |
2.9 |
1.3 |
| Octadecanoic acid |
1.3 |
-1.3 |
2.5 |
2.5 |
0.0045 |
0.79 |
1.8 |
1.1 |
| Noradrenaline |
-1.4 |
-1.3 |
2.5 |
1.0 |
0.0045 |
0.77 |
2.8 |
1.1 |
| Alanine |
1.0 |
1.0 |
2.5 |
2.2 |
0.0045 |
0.67 |
1.5 |
1.0 |
| Gulonate |
-1.1 |
1.2 |
1.9 |
1.3 |
0.0424 |
0.53 |
2.8 |
1.4 |
| 4-(3-Hydroxy-phenyl)-butyric acid |
1.2 |
1.3 |
2.1 |
-1.7 |
0.0424 |
0.86 |
1.1 |
1.1 |
| 2-Monopalmitin |
-1.3 |
-1.3 |
2.5 |
2.4 |
0.0045 |
0.73 |
1.2 |
1.2 |
| 1-Monoeleoylglycerol |
1.1 |
1.1 |
-1.9 |
1.6 |
0.2912 |
0.6 |
-1.3 |
-1.3 |
| Cholesterol |
1.3 |
1.3 |
2.5 |
2.5 |
0.0045 |
0.62 |
1.7 |
1.0 |
| Butanoic acid |
1.1 |
-1.2 |
3.0 |
3.0 |
0.0045 |
0.83 |
1.9 |
1.1 |
| D-galactose |
-1.4 |
-1.4 |
-1.8 |
-1.8 |
0.0618 |
-0.6 |
-1.3 |
-1.3 |
| Stearin |
-1.0 |
1.2 |
-1.3 |
-1.6 |
0.4649 |
0.52 |
-1.4 |
-1.5 |
| Eicosanoic acid |
-1.0 |
1.1 |
1.8 |
1.9 |
0.0618 |
0.85 |
1.4 |
1.1 |
| Tyrosine |
1.3 |
-1.0 |
2.8 |
1.2 |
0.0074 |
0.88 |
2.3 |
1.4 |
|
Note: The correlation coefficients (corr coeffs) of all compounds were calculated from a cross-validated PLS-DA model (Q2Ycum = 0.899, a satisfactory model using two components) on day 3 between the control group and model group with or without Herba Cistanches treatment. Additionally, the fold changes were tested by the nonparametric Kruskal-Wallis test. Kw (P) denotes the P values of the test. H = control group, M = model group, D = treatment group. For example, H/M/0 represents the relative fold changes (model to control) at the pre-dose state. | ||||||||
Qiu et al. Chinese Medicine 2008 3:3 doi:10.1186/1749-8546-3-3 |
||||||||